Back to Search
Start Over
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer
- Source :
- Journal of Clinical Oncology. 32:TPS668-TPS668
- Publication Year :
- 2014
- Publisher :
- American Society of Clinical Oncology (ASCO), 2014.
-
Abstract
- TPS668 Background: As a single agent, eribulin is associated with prolonged overall survival compared to treatment of physician’s choice in pts with heavily pre-treated metastatic breast cancer (MB...
- Subjects :
- Eribulin Mesylate
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Phases of clinical research
medicine.disease
Metastatic breast cancer
chemistry.chemical_compound
Breast cancer
chemistry
Trastuzumab
Internal medicine
medicine
Pertuzumab
business
Human Epidermal Growth Factor Receptor 2
medicine.drug
Eribulin
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........8cc3188e349535902f2448d94a00a96f
- Full Text :
- https://doi.org/10.1200/jco.2014.32.15_suppl.tps668